# LCP1

## Overview
LCP1, or lymphocyte cytosolic protein 1, is a gene that encodes the actin-bundling protein known as L-plastin. This protein is predominantly expressed in hematopoietic cells, such as leukocytes and T-cells, and plays a vital role in the regulation of the actin cytoskeleton, which is essential for cellular processes like motility, adhesion, and immune cell activation (Morley2013The; Tseng2018LCP1). L-plastin is characterized by its ability to stabilize actin filaments, thereby facilitating cellular migration and synapse formation (Morley2013The). The protein's function is modulated by calcium binding and phosphorylation, which influence its interaction with actin and other cellular components (Morley2013The; Kell2018Targeted). L-plastin's interactions with integrins and other proteins are crucial for its role in cell signaling and structural dynamics, impacting processes such as immune response and cancer cell invasion (Machado2021Lplastin; Tseng2018LCP1).

## Structure
LCP1, also known as lymphocyte cytosolic protein 1, is an actin-bundling protein characterized by its distinct molecular structure. The protein contains two EF-hand calcium-binding motifs at the N-terminus, which are crucial for its regulation by calcium ions (Kell2018Targeted). At the C-terminus, LCP1 has two actin-binding domains (ABD1 and ABD2), each comprising two calponin-homology regions, which facilitate its interaction with actin filaments (Kell2018Targeted). The tertiary structure of LCP1 is thought to resemble a small bundle, with the actin-binding domains positioned on opposite sides, allowing it to stabilize parallel strands of actin filaments (Kell2018Targeted).

LCP1 undergoes post-translational modifications, including phosphorylation at specific serine residues, which are important for its function (Kell2018Targeted). These modifications can influence LCP1's interaction with actin and other proteins. The protein is also known to interact with integrins, particularly the αMβ2 integrin, maintaining them in an inactive conformation and thus regulating cell adhesion (Tseng2018LCP1). LCP1's structure and modifications are integral to its role in cytoskeletal organization and cellular motility.

## Function
LCP1, also known as lymphocyte cytosolic protein 1 or L-plastin, is an actin-bundling protein primarily expressed in hematopoietic cells, including leukocytes and T-cells. It plays a crucial role in the regulation of the actin cytoskeleton, which is essential for cell motility, adhesion, and immune cell activation (Morley2013The; Tseng2018LCP1). LCP1 stabilizes actin filaments, enhancing their stability and facilitating cellular processes such as migration and synapse formation (Morley2013The).

In the context of integrin-mediated cell adhesion, LCP1 preferentially binds to the inactive form of αMβ2 integrins, maintaining them in an inactive state and thus regulating leukocyte adhesion under flow conditions (Tseng2018LCP1). This interaction is crucial for preventing excessive integrin activation, which could lead to pathological conditions like thrombosis or inflammation (Tseng2018LCP1). LCP1 also competes with other proteins like talin for integrin binding, further influencing integrin activity (Tseng2018LCP1).

LCP1's role extends to cellular signaling and motility, where it is involved in T-cell chemokine-mediated signaling and motility, necessary for normal T-cell migration and immune response (Morley2013The). Its activity is regulated by phosphorylation and calcium binding, which modulate its actin-bundling capabilities (Morley2013The).

## Clinical Significance
Alterations in the expression of the LCP1 gene, which encodes the protein L-plastin, have been implicated in various cancers. In oral squamous cell carcinoma (OSCC), LCP1 is overexpressed, correlating with increased tumor size and lymph node metastasis. Knockdown of LCP1 in OSCC cells results in reduced growth, invasiveness, and migration, suggesting its potential as a therapeutic target (Koide2017Evidence). In triple-negative breast cancer (TNBC), higher LCP1 expression is associated with favorable survival outcomes and immune cell infiltration, indicating its role as a prognostic marker (Pan2024LCP1).

In gastric cancer, LCP1 expression is linked to poor prognosis and is associated with immune cell infiltration, including CD8+ T cells and dendritic cells, suggesting its involvement in tumor immune microenvironment interactions (Zeng2021LCP1). LCP1 mutations in chronic lymphocytic leukemia (CLL) have been identified as potential drivers of the disease, affecting DNA damage response pathways and enhancing cell survival (Wang2017Integrated).

LCP1 is also overexpressed in other cancers such as prostate carcinoma, colorectal cancer, and melanoma, where it is linked to increased cell invasion and metastasis. Its phosphorylation, particularly at Ser5, is crucial for its role in cancer progression (SchaffnerReckinger2020The).

## Interactions
LCP1, also known as lymphocyte cytosolic protein 1, is involved in various protein interactions that influence cell signaling and structural dynamics. It interacts with the mTORC2 complex, specifically with mTOR and GßL, which are crucial for the phosphorylation of AKT at Ser473, a key process in cell survival and proliferation (Ma2019LCP1). LCP1 also interacts with integrins, particularly β1 and β2, which are important for cell adhesion and signaling. This interaction is significant in adipocyte biology, where LCP1 silencing leads to downregulation of integrin β1, affecting lipid metabolism and thermogenesis (Subramani2021Loss).

In the immune system, LCP1, also known as L-plastin, interacts with proteins such as grancalcin and Iba1, enhancing its actin-bundling capacity and promoting leukocyte adhesion and migration (SchaffnerReckinger2020The). It is also involved in the formation of the immunological synapse in T lymphocytes, where its phosphorylation is crucial for the transport of activation molecules like CD25 and CD69 to the cell surface (SchaffnerReckinger2020The). In cancer, LCP1 interacts with cortactin in invadopodia, structures involved in extracellular matrix degradation, which is essential for cancer cell invasion (Machado2021Lplastin).


## References


[1. (Koide2017Evidence) Nao Koide, Atsushi Kasamatsu, Yosuke Endo-Sakamoto, Sho Ishida, Toshihiro Shimizu, Yasushi Kimura, Isao Miyamoto, Shusaku Yoshimura, Masashi Shiiba, Hideki Tanzawa, and Katsuhiro Uzawa. Evidence for critical role of lymphocyte cytosolic protein 1 in oral cancer. Scientific Reports, February 2017. URL: http://dx.doi.org/10.1038/srep43379, doi:10.1038/srep43379. This article has 34 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep43379)

[2. (Morley2013The) Sharon Celeste Morley. The actin‐bundling protein l‐plastin supports t‐cell motility and activation. Immunological Reviews, 256(1):48–62, October 2013. URL: http://dx.doi.org/10.1111/imr.12102, doi:10.1111/imr.12102. This article has 53 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/imr.12102)

[3. (Kell2018Targeted) Margaret J. Kell, Rachel E. Riccio, Emily A. Baumgartner, Zachary J. Compton, Paul J. Pecorin, Taylor A. Mitchell, Jacek Topczewski, and Elizabeth E. LeClair. Targeted deletion of the zebrafish actin-bundling protein l-plastin (lcp1). PLOS ONE, 13(1):e0190353, January 2018. URL: http://dx.doi.org/10.1371/journal.pone.0190353, doi:10.1371/journal.pone.0190353. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0190353)

[4. (Zeng2021LCP1) Qingwen Zeng, Leyan Li, Zongfeng Feng, Lianghua Luo, Jianbo Xiong, Zhigang Jie, Yi Cao, and Zhengrong Li. Lcp1 is a prognostic biomarker correlated with immune infiltrates in gastric cancer. Cancer Biomarkers, 30(1):105–125, February 2021. URL: http://dx.doi.org/10.3233/cbm-200006, doi:10.3233/cbm-200006. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3233/cbm-200006)

[5. (Ma2019LCP1) Guangxin Ma, Deniz Gezer, Oliver Herrmann, Kristina Feldberg, Mirle Schemionek, Mohamad Jawhar, Andreas Reiter, Tim H. Brümmendorf, Steffen Koschmieder, and Nicolas Chatain. Lcp1 triggers mtorc2/akt activity and is pharmacologically targeted by enzastaurin in hypereosinophilia. Molecular Carcinogenesis, 59(1):87–103, November 2019. URL: http://dx.doi.org/10.1002/mc.23131, doi:10.1002/mc.23131. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/mc.23131)

[6. (Subramani2021Loss) Manigandan Subramani and Jong Won Yun. Loss of lymphocyte cytosolic protein 1 (lcp1) induces browning in 3t3-l1 adipocytes via β3-ar and the erk-independent signaling pathway. The International Journal of Biochemistry &amp; Cell Biology, 138:106053, September 2021. URL: http://dx.doi.org/10.1016/j.biocel.2021.106053, doi:10.1016/j.biocel.2021.106053. This article has 7 citations.](https://doi.org/10.1016/j.biocel.2021.106053)

[7. (Machado2021Lplastin) Raquel A. C. Machado, Dunja Stojevski, Sébastien De Landtsheer, Philippe Lucarelli, Alexandre Baron, Thomas Sauter, and Elisabeth Schaffner-Reckinger. L-plastin ser5 phosphorylation is modulated by the pi3k/sgk pathway and promotes breast cancer cell invasiveness. Cell Communication and Signaling, February 2021. URL: http://dx.doi.org/10.1186/s12964-021-00710-5, doi:10.1186/s12964-021-00710-5. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-021-00710-5)

[8. (Tseng2018LCP1) Hui-yuan Tseng, Anna V. Samarelli, Patricia Kammerer, Sarah Scholze, Tilman Ziegler, Roland Immler, Roy Zent, Markus Sperandio, Charles R. Sanders, Reinhard Fässler, and Ralph T. Böttcher. Lcp1 preferentially binds clasped αmβ2 integrin and attenuates leukocyte adhesion under flow. Journal of Cell Science, November 2018. URL: http://dx.doi.org/10.1242/jcs.218214, doi:10.1242/jcs.218214. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1242/jcs.218214)

[9. (SchaffnerReckinger2020The) Elisabeth Schaffner-Reckinger and Raquel A.C. Machado. The actin-bundling protein L-plastin—A double-edged sword: Beneficial for the immune response, maleficent in cancer, pages 109–154. Elsevier, 2020. URL: http://dx.doi.org/10.1016/bs.ircmb.2020.05.004, doi:10.1016/bs.ircmb.2020.05.004. This article has 9 citations.](https://doi.org/10.1016/bs.ircmb.2020.05.004)

[10. (Wang2017Integrated) Lili Wang, Jean Fan, Joshua M. Francis, George Georghiou, Sarah Hergert, Shuqiang Li, Rutendo Gambe, Chensheng W. Zhou, Chunxiao Yang, Sheng Xiao, Paola Dal Cin, Michaela Bowden, Dylan Kotliar, Sachet A. Shukla, Jennifer R. Brown, Donna Neuberg, Dario R. Alessi, Cheng-Zhong Zhang, Peter V. Kharchenko, Kenneth J. Livak, and Catherine J. Wu. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Research, 27(8):1300–1311, July 2017. URL: http://dx.doi.org/10.1101/gr.217331.116, doi:10.1101/gr.217331.116. This article has 70 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1101/gr.217331.116)

[11. (Pan2024LCP1) Shuaikang Pan, Mengting Wan, Hongwei Jin, Ran Ning, Jinguo Zhang, and Xinghua Han. Lcp1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer. BMC Immunology, July 2024. URL: http://dx.doi.org/10.1186/s12865-024-00635-x, doi:10.1186/s12865-024-00635-x. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12865-024-00635-x)